Skip to main content
. 2014 Nov 27;9(2):626–630. doi: 10.3892/etm.2014.2093

Figure 2.

Figure 2

Meta-analysis of clinical response of mTOR inhibitor versus non-mTOR inhibitor therapy. The risk ratio was 24.71 (95% CI, 7.46–81.72; P<0.001). There was no evidence of significant heterogeneity between trials (P=0.13, I2=32%). mTOR, mammalian target of rapamycin; CI, confidence interval.